The biotech industry thrived during the pandemic with rising demand for drugs, therapies, and vaccines. However, various macroeconomic and regulatory challenges have hampered the industry’s growth since last year, prompting massive layoffs and shutdowns.
Regardless of the challenges being faced by the industry, investors should not shy away from buying fundamentally sound biotech stocks Gilead Sciences, Inc. (GILD), Vertex Pharmaceuticals Incorporated (VRTX), and Biogen Inc. (BIIB) for solid returns.
